Projects funded by the NCN
Effectiveness of anticancer activity of DMU-214 (3'-hydroxy-3,4,5,4'-tetrametoxystilbene) in personalized treatment for ovarian cancer
2016/23/D/NZ7/03954
Keywords:
methylated resveratrol analogues DMU-214 CYP1A1 p53 oxygen hypoxia 3D cell culture model mice xenograft model
Descriptors:
- NZ5_7:
- NZ7_14:
- NZ7_15:
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Farmaceutyczny
woj. wielkopolskie
Principal investigator (from the host institution):
dr hab. Hanna Helena Piotrowska-Kempisty
Number of co-investigators in the project: 7
Call: SONATA 12 - announced on 2016-09-15
Amount awarded: 990 889 PLN
Project start date (Y-m-d): 2017-09-20
Project end date (Y-m-d): 2023-09-19
Project duration:: 72 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- Enhanced biological activity of liposomal methylated resveratrol analog 3′-hydroxy-3,4,5,4′-tetramethoxystilbene (DMU-214) in 3D patient-derived ovarian cancer modelAuthors:Andrzej Nowicki, Dariusz Wawrzyniak, Mikołaj Czajkowski, Małgorzata Józkowiak, Michał Pawlak, Marcin Wierzchowski, Katarzyna Rolle, Paulina Skupin-Mrugalska, Hanna Piotrowska-KempistyAcademic press:Drug Delivery (rok: 2022, tom: 29, strony: 2459-2468), Wydawca: taylor & francisStatus:PublishedDOI:10.1080/10717544.2022.2103210 - link to the publication